Research Papers:

MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells

Chen-Ying Liu, Siew Wee Chan, Fusheng Guo, Aleksandra Toloczko, Long Cui and Wanjin Hong _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:13706-13716. https://doi.org/10.18632/oncotarget.7333

Metrics: PDF 2877 views  |   HTML 2770 views  |   ?  


Chen-Ying Liu1,2, Siew Wee Chan1, Fusheng Guo1, Aleksandra Toloczko1, Long Cui2, Wanjin Hong1

1Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Proteos, Singapore 138673, Singapore

2Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China

Correspondence to:

Wanjin Hong, e-mail: [email protected]

Long Cui, e-mail: [email protected]

Keywords: Hippo pathway, TAZ, MRTF/SRF, Heregulin β1 (HRG1), breast cancer

Received: November 11, 2015     Accepted: January 29, 2016     Published: February 11, 2016


Dysregulation of Hippo pathway results in activation of transcriptional co-activators YAP/TAZ in breast cancer. Previously, we showed that overexpression of TAZ in breast cancer promotes cell migration, invasion and tumorigenesis. Here, we show that upregulation of TAZ in breast cancers could also be due to dysregulation of TAZ transcription. Heregulin β1 (HRG1) increases TAZ mRNA level in breast cancer cells. TAZ is a direct target of MRTF/SRF transcriptional factors which are activated by HRG1. Both MRTF/SRF and TAZ are the important downstream effectors enhancing cell migration induced by HRG1. TAZ mRNA level is correlated with nuclear localization of MRTF in breast cancer cells and the mRNA level of MRTF/SRF direct target genes in breast cancers, indicating the correlation between MRTF/SRF activity and TAZ expression. Our results provide new insights into the transcriptional regulation of TAZ and dysregulation mechanism of TAZ in breast cancer, which could be a new therapeutic strategy for breast cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7333